Acadian Asset Management
YMAB

Acadian Asset Management’s Y-mAbs Therapeutics YMAB Stock Holding History

Acadian Asset Management’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-105,777
Closed -$1.39M – 2227
2024
Q3 		$1.39M Sell
105,777
-217,398
-67% -$2.76M ﹤0.01% 848
2024
Q2 		$3.9M Sell
323,175
-279,139
-46% -$3.77M 0.01% 568
2024
Q1 		$9.79M Sell
602,314
-200,067
-25% -$2.7M 0.03% 303
2023
Q4 		$5.47M Sell
802,381
-8,880
-1% -$51.4K 0.02% 423
2023
Q3 		$4.42M Buy
811,261
+157,173
+24% +$915K 0.02% 478
2023
Q2 		$4.44M Buy
654,088
+254,506
+64% +$1.91M 0.02% 489
2023
Q1 		$2M Buy
399,582
+201,022
+101% +$821K 0.01% 714
2022
Q4 		$968K Buy
+198,560
New +$1.44M ﹤0.01% 856

Other funds holding YMAB

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acadian Asset Management's YMAB Position: Q4 2024 in Review

Acadian Asset Management sold out of Y-mAbs Therapeutics (YMAB) in Q4 2024, closing a stake of 105,777 shares — an estimated $1.39M sold.

Acadian Asset Management first reported a position in YMAB in Q4 2022 and held it in 8 quarters. The position peaked at $9.79M in Q1 2024. 112 funds tracked by Wall St. Rank hold YMAB as of Q4 2024.

  • Acadian Asset Management reported no remaining Y-mAbs Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Acadian Asset Management sold 105,777 Y-mAbs Therapeutics shares in Q4 2024, an estimated $1.39M.
  • Acadian Asset Management first reported a position in Y-mAbs Therapeutics in Q4 2022 and held it in 8 quarters.
  • Acadian Asset Management's Y-mAbs Therapeutics position peaked at $9.79M in Q1 2024.
  • 112 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q4 2024.

Based on Acadian Asset Management's 13F filing for Q4 2024, filed 11 Feb 2025.